Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCOTREAT

Financiado

Cerrado

Identification of Novel Targeted Therapies for Renal Cancer

Overall, kidney cancers are the eighth most common cancer and the incidence of the most common form (renal cell carcinoma, RCC) has been increasing steadily over the past 30 years. If detected early, surgical removal of RCC can be... ver más

31/08/2019

THE CHANCELLOR MAS...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2019-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

THE CHANCELLOR MASTERS AND S...

0.00€ | Lider

UoB

N.D. | Participante

Proyectos interesantes

CARE1

Medical Technol...

Data Science

6M€ Cerrado

PID2021-128312OB-I00

Medical Technol...

Data Science

196K€ Cerrado

RTI2018-095039-B-I00

Medical Technol...

Data Science

109K€ Cerrado

SAF2015-70820-ERC

Medical Technol...

Data Science

60K€ Cerrado

TECNEC

Medical Technol...

Data Science

3M€ Cerrado

EUROTARGET

Medical Technol...

Data Science

8M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Overall, kidney cancers are the eighth most common cancer and the incidence of the most common form (renal cell carcinoma, RCC) has been increasing steadily over the past 30 years. If detected early, surgical removal of RCC can be curative but the prognosis for metastatic disease is very poor. RCC is resistant to conventional therapy and recently introduced targeted therapies form the mainstay of treatment for metastatic disease. The rationale for the use of targeted therapies (e.g. antiangiogenic tyrosine kinase inhibitors) in RCC was derived from functional investigations of the mechanism of tumourigenesis in the rare inherited RCC syndrome von Hippel-Lindau disease. Whilst currently available targeted therapies can extend progression free survival in advanced RCC they are not curative and better treatments are urgently required. Large scale genomic studies of RCC are in progress and will greatly enhance current knowledge of the molecular pathology of RCC. However, experience from other cancers suggests that the results of genomic analyses of cancer are complex and identifying the key gatekeeper genes is frequently challenging. ONCOTREAT is based on the hypothesis that (a) the identification of the genetic basis of inherited forms of RCC will highlight those genes and pathways that are critical for tumourigenesis and (b) that selective targeting of cells deficient in inherited RCC gene function will enable advances in the treatment of inherited and sporadic RCC. The objectives of ONCOTREAT are to: 1. Identify novel inherited RCC genes 2. Generate and characterise human cell line models for inherited RCC genes 3. Identify candidate therapeutic agents that, in in vitro studies, selectively target human cell line models of inherited RCC genes dysfunction 4. Evaluate candidate therapeutic agents identified from in vitro studies in in vivo investigations to identify agents that target cancers deficient in inherited RCC gatekeeper genes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores